Skip to main content

Advertisement

Table 1 Ongoing clinical trials of osimertinib (AZD9291, TAGRISSO)

From: Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Phase Study population NCT no.
Phase Ib EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02143466
Phase I EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI and standard therapy 02157883
Phase I EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02317016
Phase III (ADAURA) EGFR mutated stage IB–IIIA NSCLC following complete resection with or without adjuvant chemotherapy 02511106
Phase I EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02197234
Phase III EGFR mutated advanced NSCLC 02296125
Phase III EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI 02474355
Phase III EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI 02151981
Phase I EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02503722
Phase I EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02496663
Phase I/II EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 01802632
Phase I EGFR mutated advanced NSCLC 02228369
Phase II EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI 02094261
Phase II EGFR T790M mutation-positive NSCLC progressed following therapy with an EGFR TKI 02442349
Phase Ib EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02520778
Phase IIa Stage IIIB–IV locally advanced or metastatic NSCLC 02179671
Phase I Chinese patients with EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02529995
Phase II EGFR mutated advanced NSCLC progressed following therapy with an EGFR TKI 02504346
  1. EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer, TKI: tyrosine kinase inhibitor